Loading...
01/11 07:34
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals strong financial performance with an 87% revenue increase and improved gross margins. Positive guidance with 70%-75% growth expectations, supported by a robust pipeline, indicates optimism. The Q&A highlights significant commercial payer rates and Medicare reimbursement progress, enhancing profitability potential. While there are competitive and operational risks, the company's strategic focus on reimbursement and market access, along with promising clinical outcomes, supports a positive outlook. Despite some management vagueness, the overall sentiment is positive, likely resulting in a 2%-8% stock price increase.
Revenue $5.3 million in Q3 2025, up 87% from $2.8 million in Q3 2024. This increase was driven by $4.1 million from recurring revenue and $1.2 million from one-time sales of capital equipment.
Gross Margin 74.3% in Q3 2025, compared to 63.1% in Q3 2024. The improvement reflects growing efficiency and scale of commercial operations.
Operating Expenses $12.8 million in Q3 2025, up from $10.8 million in Q3 2024. The increase is attributed to R&D and SG&A expenses.
Net Loss $8 million or $0.26 per share in Q3 2025, down from $9.4 million or $0.38 per share in Q3 2024. The reduction in net loss is due to increased revenue and improved gross margins.
Cash Position $24.8 million as of September 30, 2025. The company expects cash burn to decline as revenue grows and margins remain high.
TULSA-AI Volume Reduction software: Full product release to be launched at RSNA 2025. Designed to shrink benign and large prostates caused by BPH. Offers AI-powered planning and accelerated ablation with efficient workflows. Early surgeon feedback has been positive, with increased utilization expected in 2026.
Sonalleve: Technology for treating uterine fibroids, adenomyosis, and potentially pancreatic cancer. Currently operational in Europe, China, and Southeast Asia. Over 4,000 women treated for uterine conditions. Potential for expansion in Gulf countries and Brazil.
TULSA-PRO adoption: Broader adoption across academic and community hospitals. 70 TULSA-PRO sites operational, with 93 new systems in the sales pipeline. Strategic partnerships established in Saudi Arabia, Australia, New Zealand, and with Siemens.
Sonalleve market expansion: Interest from Gulf region countries and Brazil for interventional MRI and Sonalleve technology.
Revenue growth: Q3 2025 revenue increased by 87% year-over-year to $5.3 million. Gross margin improved to 74% from 63% in Q3 2024.
Cost management: Net loss reduced to $8 million in Q3 2025 from $9.4 million in Q3 2024. Cash burn expected to decline as revenue grows.
Profitability strategy: Focus on achieving 200 TULSA-PRO sites with 50 procedures per site annually. Targeting $85 million annual revenue with high margins to achieve profitability.
AI-powered software upgrade: Upgrading software to include simpler workflows for BPH patients, enabling efficient scheduling and treatment days.
Financial Performance: The company recorded a net loss of $8 million in Q3 2025, though it was an improvement from the $9.4 million loss in Q3 2024. Operating expenses increased to $12.8 million from $10.8 million in the same period last year, which could strain financial resources if revenue growth does not keep pace.
Future Financing Uncertainty: The company has no immediate plans for financing but intends to file an S-3 registration to keep options open. This could lead to shareholder dilution if financing becomes necessary.
Regulatory and Reimbursement Challenges: While some commercial payers are covering procedures on a case-by-case basis, there are still instances of initial denials and appeals. This mixed reimbursement landscape could hinder broader adoption of the technology.
Market Adoption Risks: Although the TULSA-PRO platform is gaining traction, broader adoption depends on achieving compatibility with new Siemens Interventional MR systems and securing national or regional coverage decisions from commercial payers.
Competitive Pressures: The company faces competition from other prostate treatment technologies like HIFU, IRE, and cryotherapy. While TULSA-PRO offers unique features, convincing clinicians to adopt it over existing methods remains a challenge.
Supply Chain and Distribution Risks: The company relies on strategic partnerships and distribution agreements in various regions. Any disruptions in these partnerships could impact market penetration and revenue growth.
Economic and Operational Risks: The company’s profitability depends on scaling operations and achieving high utilization rates at TULSA-PRO sites. Economic downturns or operational inefficiencies could delay profitability.
Revenue Growth: The company expects to achieve high double-digit growth with high margins, aiming for profitability and continued profitable growth.
Cash Flow: Profound Medical anticipates a decline in cash burn and eventual transition to cash flow positive as revenue grows and margins remain high.
TULSA-AI Volume Reduction Software: The full product release will be launched at the RSNA annual meeting, with expectations to increase utilization in BPH procedures to double-digit percentages of total procedures in 2026.
TULSA-PRO Expansion: The company aims to achieve an installed base of 200 TULSA-PRO sites, with 50 procedures per site per year, generating $55 million in procedure revenue, $10 million in annual service revenue, and $20 million in new capital revenue.
Reimbursement and Coverage: Profound Medical expects to secure national or regional coverage decisions from commercial payers starting mid-2026, supported by clinical data.
Sonalleve Technology: The company plans to expand the use of Sonalleve for treating uterine fibroids, adenomyosis, and potentially pancreatic cancer, with increasing interest from international markets.
The selected topic was not discussed during the call.
The earnings call reveals strong financial performance with an 87% revenue increase and improved gross margins. Positive guidance with 70%-75% growth expectations, supported by a robust pipeline, indicates optimism. The Q&A highlights significant commercial payer rates and Medicare reimbursement progress, enhancing profitability potential. While there are competitive and operational risks, the company's strategic focus on reimbursement and market access, along with promising clinical outcomes, supports a positive outlook. Despite some management vagueness, the overall sentiment is positive, likely resulting in a 2%-8% stock price increase.
The earnings call highlights strong financial performance with improved gross margins and revenue growth. The CAPTAIN trial data and positive feedback from physicians enhance confidence in TULSA's efficacy. Although there are increased operating expenses and net losses, management's optimistic guidance, strategic partnerships, and successful marketing initiatives signal potential for growth. The Q&A session confirms positive sentiment, with plans for reduced cash burn and strategic expansions. The absence of negative guidance, coupled with favorable reimbursement scenarios, supports a positive outlook for the stock price over the next two weeks.
The earnings call presents a mixed picture: strong revenue growth and promising product development (TULSA AI and CAPTAIN trial) are offset by increased net losses and operating expenses. The Q&A section reveals positive feedback on CAPTAIN data and insurer engagement, but management's vague responses on deal closures and financial guidance introduce uncertainty. The lack of shareholder return initiatives further tempers optimism. Despite potential for future growth, current financial instability and competitive pressures suggest a neutral stock price movement in the short term.
The earnings call reveals a significant revenue increase, improved margins, and strategic product launches, suggesting strong growth potential. Despite some regulatory and competitive risks, the introduction of new products and market expansion plans are promising. The Q&A section shows confidence in growth, albeit with some vagueness on specifics. Overall, the positive financial performance and future growth expectations outweigh the uncertainties, indicating a positive stock movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
